Redeye: Calliditas Therapeutics: Key competitor fails; advantage Calliditas/Nefecon

A key competitor to Calliditas/Nefecon failed their first placebo-controlled clinical test. Together with additional data presented around Nefecon's potential for the treatment of IgA nephropathy, we believe that Calliditas' position has been strengthened and see a good case in the stock going forward.

Read more and download the initial analysis: http://bit.ly/2DQBZJ1

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/